On the 17th, Mitsubishi Tanabe Pharma announced that the company had signed a domestic marketing agreement with Sanofi Aventis Korea for Sanofi’s amyotrophic lateral sclerosis (ALS) treatment ‘Rilutek (riluzole)’ on the 12th.

Rilutek is the first treatment for ALS approved by the US FDA. The drug is used to extend survival or delay the need for a tracheostomy in ALS patients.

Under the marketing agreement, Mitsubishi Tanabe Pharma Korea will own exclusive marketing rights for Rilutek. The company was able to offer a broader treatment option for the disease with the ALS injection treatment 'Radicut (ingredient: edaravone)' that was approved in the US in June 2016.

AL